Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with FLOAP for Gastric/Gastroesophageal Junction Cancer
NCT05033392Phase 2Recruiting
- Sponsor
- Shenzhen Wanhe Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Shenzhen Wanhe Pharmaceutical. Started Sep 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05033392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033392.